The putative therapeutic value of high-dose selenium in proliferative retinopathies may reflect down-regulation of VEGF production by the hypoxic retina
- 31 December 2005
- journal article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 64 (1), 159-161
- https://doi.org/10.1016/j.mehy.2002.11.003
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody FragmentAmerican Journal of Ophthalmology, 2002
- Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulationMolecular Carcinogenesis, 2000
- Role of vascular endothelial growth factor in diabetic vascular complicationsKidney International, 2000
- Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intakeMolecular Carcinogenesis, 1999
- Chemopreventive mechanisms of seleniumMedizinische Klinik - Intensivmedizin und Notfallmedizin, 1999
- Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductaseCarcinogenesis: Integrative Cancer Research, 1999
- Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Some properties of murine selenocysteine synthaseBiochemical Journal, 1992
- Potential clinical applications for high-dose nutritional antioxidantsMedical Hypotheses, 1984